Flerie-backed Atrogi reports positive proof-of-mechanism data for ATR-258 in overweight, obese patients

• Flerie reported positive proof-of-mechanism results from Atrogi’s ATR-258 study in overweight or obese participants.
• Results have already been presented, based on an eight-week, open-label, single-arm trial in 13 otherwise healthy individuals.
• ATR-258 was well tolerated, showing improved physical function with gains in lean mass alongside reduced fat mass.
• Data underpin plans to start a Phase 2 trial in 2027, signaling continued investment in clinical development.
• Flerie holds 47% of Atrogi, making progress on ATR-258 potentially material to portfolio value.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Flerie AB published the original content used to generate this news brief on October 01, 2026, and is solely responsible for the information contained therein.